Copyright
©The Author(s) 2018.
World J Gastroenterol. Feb 21, 2018; 24(7): 852-861
Published online Feb 21, 2018. doi: 10.3748/wjg.v24.i7.852
Published online Feb 21, 2018. doi: 10.3748/wjg.v24.i7.852
Figure 1 Efficacy of treatment.
Sustained virological response rates 12 wk after the end of treatment (SVR 12) are shown for patients with HCV genotype 1, 2, 3 or 4 (A-D). Patients were sub-classified for therapy regime and treatment duration.
- Citation: Steinebrunner N, Stein K, Sandig C, Bruckner T, Stremmel W, Pathil A. Predictors of functional benefit of hepatitis C therapy in a ‘real-life’ cohort. World J Gastroenterol 2018; 24(7): 852-861
- URL: https://www.wjgnet.com/1007-9327/full/v24/i7/852.htm
- DOI: https://dx.doi.org/10.3748/wjg.v24.i7.852